Navigation Links
Brookhaven Lab and BioSET patent a synthetic peptide that enhances bone growth
Date:2/19/2009

UPTON, NY Brookhaven Science Associates, the company that operates and manages the U.S. Department of Energy's Brookhaven National Laboratory (BNL), and Biosurface Engineering Technologies, Inc. (BioSET), have been issued a U.S. patent on a synthetic peptide, called B2A.

"About 250,000 Americans undergo lumbar spine fusion surgeries each year to treat lower back pain," said Tom Rouche, BioSET President and CEO. "We have developed a novel combination medical device, called AMPLEX, that incorporates B2A osteo-inductive growth factor with an ultra-high grade ceramic bone substitute for use in this type of surgery. Preclinical studies have found that it is a safe and highly effective."

B2A enhances the effects of a tissue growth factor known as bone morphogenetic protein 2, or BMP-2. BMPs are a family of proteins in the human body responsible for the proliferation, repair and differentiation of cells in many tissues, including bone.

Brookhaven Lab scientist Louis Pea developed B2A with BioSET, and he performed the initial studies at Brookhaven. "I became interested in bone growth factors after NASA built a radiation research facility at Brookhaven," Pea said. "Weightlessness in space causes bone loss, and cosmic radiation can cause damage to cells, so I thought I might be able to study the interaction of the two. In setting up for that, I developed B2A and couldn't ignore its biomedical applications, so I focused on it instead. The ability to shift direction and follow promising leads is important in science, and I've had the freedom to do that at Brookhaven. I am gratified that BioSET has been able to take the B2A technology to a new level of clinical testing."

In recent preclinical studies, University of Iowa researchers used a rabbit model to evaluate AMPLEX spine fusion. They found that it enhanced the fusion, compared to a conventional surgical method that uses the rabbit's own pelvic bone to form the bone graft. Also, a team of researchers assembled by BioSET reported at a 2008 Orthopedic Research Society meeting that AMPLEX enhanced spine fusion in sheep, a large animal model that more closely resembles the human spine.

BioSET has received approval from the U.S. Food and Drug Administration to initiate a pilot study to evaluate the safety and preliminary efficacy of AMPLEX in approximately 22 patients. Also, the company received approval from Health Canada for a similar study with 24 patients in that country. Each controlled study will compare AMPLEX to an autograft from the patient's own hip bone in lumbar fusion procedures to treat degenerative disc disease.

The first patient surgery in the Canadian study was performed by a neurosurgeon at Foothills Medical Centre in Calgary, Canada. The surgeon reported that AMPLEX handled as well as other ceramic graft alternatives and the patient was recovering well after surgery. Data from all patients in the clinical studies will be evaluated at six-month intervals.

The initial research to develop B2A was funded by the U.S. Department of Energy's Office of Science, the National Institutes of Health, and BioSET. The patent on B2A (Patent # US 7,482,427 B2), titled "Positive Modulator of Bone Morphogenic Protein-2," was issued on January 27, 2009.


'/>"/>

Contact: Diane Greenberg
greenb@bnl.gov
631-344-2347
DOE/Brookhaven National Laboratory
Source:Eurekalert

Related medicine news :

1. Brookhaven scientists explore brains reaction to potent hallucinogen
2. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
3. Spectranetics to Appeal Decision in Patent Litigation
4. Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs
5. Actavis Confirms its Patent Challenge of Kings Avinza(R)
6. PartsSource Awarded US Patent for PartsFinder(TM) Application
7. Barr Confirms Patent Challenge of UROXATRAL(R)
8. Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione
9. VNUS Medicals Patent Lawsuit Against Laser Competitors to Proceed to Trial
10. Aida Granted Additional Anti-Cancer Patent
11. China Medicines ADTZ Project Has Been Selected as One of Six Patent Commercialization Projects in Guangdong Province
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... Durham, NC (PRWEB) , ... March 30, 2017 ... ... professionals, will host the live audio conference “ Preventing Hospital Readmissions Through Discharge ... April 12, 2017 at 1:00 pm ET. This conference discusses strategies to prevent ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS ... Medical Center will serve as the official title sponsor of the Baltimore Women’s Classic, ... 2017, thousands of women will walk or run the course around the Baltimore Inner ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy ... attending prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. ... recognized as the visionary leader in the training of physicians, scientists, and members ...
(Date:3/29/2017)... ... 29, 2017 , ... Patients interested in receiving quick and ... Jamie Cameron, with or without a referral. The FASTBRACES system is valued for ... each patient’s case, treatment with the FASTBRACES system could be completed in 120 ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017 Research and Markets has announced the ... to their offering. ... The global gas chromatograph market to grow at a CAGR ... Global Gas Chromatograph Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:3/29/2017)... 29, 2017  Novartis announced today that the ... the company,s Biologics License Application (BLA) filing and ... chimeric antigen receptor T cell (CAR-T) therapy, in ... patients with B-cell acute lymphoblastic leukemia (ALL). This ... a CAR-T. The priority review designation is expected ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... Centers & Forecast" report to their offering. ... The South Korean Proton Therapy Market is expected ... The Untapped Proton Therapy Market for South Korea ... Proton Therapy plays an important role in delivering comprehensive cancer care ...
Breaking Medicine Technology: